Why Allakos Stock Plummeted 87.5% in the Last Month of 2021
- Oops!Something went wrong.Please try again later.
- ALLK
Allakos published phase 3 Enigma 2 and phase 2/3 Kryptos trial data on its lirentelimab monoclonal antibody as a treatment for eosinophilic gastrointestinal diseases (EGIDs), and the results shocked the market. Lirentelimab had shown promising results as a treatment for eosinophilic gastrointestinal diseases in its phase 2 trials, and the phase 3 data caught the market off guard. The crushing study results were followed by a series of downgrades from high-profile analysts.